Hyperfine (HYPR) announced it has received CE Marking and UK Conformity Assessment, UKCA, approval for both the next-generation Swoop system and the latest advancement in its Optive AI software. Together, these regulatory approvals enable commercialization of Hyperfine’s most advanced portable MRI technology across Europe and the United Kingdom, expanding access to high-quality brain imaging at the point of care and representing a pivotal milestone in the company’s international commercial growth strategy.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HYPR:
- Hyperfine’s Portable MRI Trial Update Puts Contrast Imaging in the Spotlight
- Horizon Technology provides $40M loan facility to Hyperfine
- Hyperfine Inc. Exposed to Rising Credit Risk as Delayed Customer Payments Threaten Cash Flow and Financial Stability
- Hyperfine Inc. Earnings Call Signals Commercial Breakthrough
- Hyperfine price target raised to $1.60 from $1.30 at B. Riley